MIRM - Mirum Pharmaceuticals Inc logo

Mirum Pharmaceuticals Inc

MIRM

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its products include LIVMARLI for Alagille syndrome, Cholbam for bile acid synthesis disorders, and Chenodal for radiolucent gallbladder stones, among others.

⚕️ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago →$4,689today

Score Overview

1 Year
Score
Net Growth-34x
Net TrendShrank
Net Income Consistency—
Rev Growth-15.25%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.0
Net Growth-8x
Net Trend40%
Net Income Consistency—
Rev Growth23x
Rev Trend80%
Revenue Consistency—
All Time
Score—
Net Growth-14x
Net Trend43%
Net Income Consistency
Rev Growth—
Rev Trend86%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Mirum Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. MIRM does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 87.54—
1 Year2025-09-29
$ 72.8520.16%
5 Years2021-09-29
$ 18.67368.88%
All Time2019-07-18
$ 13.216x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 441M-$ 860M$ 438M
2025$ 521M-$ 23M$ 383M
2024$ 336M-$ 87M$ 280M
2023$ 186M-$ 163M$ 286M
2022$ 77M-$ 135M$ 151M
2021$ 19M-$ 83M$ 156M
2020$ 11M-$ 103M$ 231M
IPO2019$ 0.00-$ 52M$ 116M
MIRM - Mirum Pharmaceuticals Inc logo

Mirum Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 11M to $ 521M and net income went from -$ 103M to -$ 23M. Revenue increased in 4 of those 5 years; net income in 2.

Mirum Pharmaceuticals Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Explore MIRM with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies